Evidence question

PubMed sourcedAbstract-based analysisUpdated Sep 2026

Evidence / Men's Sexual Health

CoverageMen's Sexual Health

Are PDE5 inhibitors safe for cardiovascular disease in men with erectile dysfunction?

Updated Sep 2026·12 studies analyzed·2 core studies·Applies to: hypogonadal men

Bottom line

In stable cardiovascular disease, PDE5 inhibitors do not appear to increase major adverse cardiac events when used appropriately and nitrate co-administration is avoided. Sexual activity itself carries modest cardiovascular demand; individualized assessment remains important after recent events.[1–6]

Evidence confidence

Evidence Confidence

High
LimitedModerateHigh

Multiple high-quality studies directly address this question, with generally consistent findings.

Key uncertainty. Data in unstable angina or very recent myocardial infarction are more limited; timing of resumption requires clinical judgment.

Ask RAGMD

Get the live evidence synthesis

10 complimentary queries. Full clinical intelligence — PubMed citations, conflict analysis, Evidence Confidence — with 7-day free trial.

Also asked

Sildenafil cardiovascular safety▼

In stable cardiovascular disease, PDE5 inhibitors do not appear to increase major adverse cardiac events when used appropriately and nitrate co-administration is avoided. Sexual activity itself carries modest cardiovascular demand; individualized assessment remains important after recent events.

PDE5 inhibitor heart attack risk▼

In stable cardiovascular disease, PDE5 inhibitors do not appear to increase major adverse cardiac events when used appropriately and nitrate co-administration is avoided. Sexual activity itself carries modest cardiovascular demand; individualized assessment remains important after recent events.

ED drugs safe after MI▼

In stable cardiovascular disease, PDE5 inhibitors do not appear to increase major adverse cardiac events when used appropriately and nitrate co-administration is avoided. Sexual activity itself carries modest cardiovascular demand; individualized assessment remains important after recent events.

Body of evidence

Clinical Evidence Brief

RAGMD analyzed 4 relevant studies.

Overall finding

4 studies address erectile function, with weighted findings showing benefit. 2 studies address sexual desire, with weighted findings showing benefit. 2 studies address sexual activity, with weighted findings showing benefit. 2 randomized or systematic-review reports and 0 observational studies address treatment. In stable cardiovascular disease, PDE5 inhibitors can be used with appropriate counseling when nitrates are not co-prescribed. Coordinate with cardiology after recent events and assess functional capacity before resuming sexual activity.

Evidence by outcome

Direction: ↑ Favors treatment / reassuring · ↓ Harm signal · ↔ No clear effect · ± Mixed · ↗ Observational link · ? Unclear

Reassuring

Erectile function

high · 4 studies

4 studies address erectile function, with weighted findings showing benefit.

Mixed measurement

Reassuring

Sexual desire

high · 2 studies

2 studies address sexual desire, with weighted findings showing benefit. This is a patient-reported / subjective outcome.

Patient-reported

Reassuring

Sexual activity

high · 2 studies

2 studies address sexual activity, with weighted findings showing benefit. This is a patient-reported / subjective outcome.

Patient-reported

Magnitude / clinical importance

Validated effect estimates in the analyzed set include or 100; mean difference=2.31. Statistical significance is not the same as clinical importance.

Interpret magnitude in absolute terms for the patient in front of you, not from relative estimates alone.

Agreement across studies

Findings are mostly consistent with minor variation after weighting by design, quality, and directness.

Supports main conclusion: 2 · Neutral / mixed: 2 · Credible conflicting: 0

Study counts describe the landscape; RAGMD weights studies according to design, quality, and directness.

Conflicting findings

  • Oral sildenafil is an effective, well-tolerated treatment for men with erectile dysfunction.
  • The most important advantage of the model is to simulate realistic target lesions like those encountered in clinical practice in endoscopic submucosal dissection training.

Who this applies to

Most studies included hypogonadal men.

What remains uncertain

  • Data in unstable angina or very recent myocardial infarction are more limited; timing of resumption requires clinical judgment.
  • Data in unstable angina or very recent myocardial infarction are more limited; timing of resumption requires clinical judgment.

Clinical takeaway

In stable cardiovascular disease, PDE5 inhibitors can be used with appropriate counseling when nitrates are not co-prescribed. Coordinate with cardiology after recent events and assess functional capacity before resuming sexual activity.

Reassuring

Erectile function?

Benefit

high[9580646 · 28434676 · 27355400 · 21679942]

Reassuring

Sexual desire?

Benefit

high[28434676 · 27355400]

Reassuring

Sexual activity?

Benefit

high[28434676 · 27355400]

2 randomized or systematic-review reports and 0 observational studies address treatment. Weighted treatment findings show benefit.

2 RCT / systematic review · 0 observational

Large randomized trials strongly influence the conclusion

2 landmark studies with randomized or systematic-review designs strongly inform this conclusion.

Supporting studies provide additional context

10 supporting studies add context beyond the core evidence base.

Regimen & duration

Differences in hormone type, dose, duration, and patient population affect how results should be interpreted.

Long-term uncertainty

Evidence beyond long follow-up windows and in certain subgroups remains less complete.

4 analyzed studies

Strongest evidence

Supporting literature

Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores.

Testosterone Treatment and Sexual Function in Older Men With Low Testosterone Levels.

Interleukin 2 treatment does not modify hepatitis B or C replication in human immunodeficiency virus-infected patients: results from a randomized control trial.

+7 more

More in this focus area

Related evidence analyses

Other structured clinical questions in Men's Sexual Health.

Go deeper on Men's Sexual Health

Full evidence synthesis, study comparisons, conflicting evidence, and expert commentary are available with RAGMD. Ask follow-up questions, explore related topics, and see how the evidence has evolved.